Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons
20 November 2024 - 12:30AM
Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a
global market leader delivering life-changing solutions to
revolutionize what is possible in rehabilitation, recovery, and the
pursuit of life’s passions in the face of physical limitation or
disability, today applauded the decision by the government of
Hungary to establish a new state insurance code to provide coverage
for exoskeleton training for individuals living with spinal cord
injury.
This coverage policy follows research conducted by Dr. Péter
Cserháti MD, PhD, Director of the Semmelweis University
Rehabilitation Clinic in Budapest, Hungary, which examined the
long-term therapeutic benefits of rehabilitation with the ReWalk
Exoskeleton. "The active lifestyle achieved by exoskeletons has a
proven positive effect on the prevention of potential health
complications for those living with spinal cord injury," emphasized
Dr. Cserháti. He reported that the ReWalk system has been available
in Hungary since 2019 at the National Medical Rehabilitation
Institute, the legal predecessor of Semmelweis University's
Rehabilitation Clinic.
“The leadership of Hungary’s government, medical community and
administrators has the potential to improve the lives of many of
its citizens living with spinal cord injury. With this decision,
access to exoskeletons has now been expanded to include Germany,
the United States and Hungary, and these policies are essential
drivers for our industry,” said Larry Jasinski, CEO of Lifeward.
“Our ongoing strategic path is expansion of coverage by Private
Insurers, Medicare Advantage and others in the United States and
adding further contracts in Germany. We also encourage health care
systems in other countries to follow Hungary’s progressive vision
for the paralyzed community.”
Zoltán Vadászi, the business line manager of the national
distributor Fototronic Kft., emphasized that ReWalk is currently
the only exoskeleton that has both US and EU official certification
(FDA, CE/MDR) and is also allowed to be used at home to ensure
independent walking. There are about 300 new cases of spinal cord
injury in Hungary annually.
About LifewardLifeward designs, develops,
and commercializes life-changing solutions that span the continuum
of care in physical rehabilitation and recovery, delivering proven
functional and health benefits in clinical settings as well as in
the home and community. Our mission at Lifeward is to relentlessly
drive innovation to change the lives of individuals with physical
limitations or disabilities. We are committed to delivering
groundbreaking solutions that empower individuals to do what they
love. The Lifeward portfolio features innovative products including
the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the
MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United
States, Israel, and Germany. For more information on the
Lifeward product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are
registered trademarks of Lifeward Ltd. and/or its
affiliates.
Forward-Looking StatementsIn addition to
historical information, this press release contains forward-looking
statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995, Section 27A of
the U.S. Securities Act of 1933, as amended, and Section
21E of the U.S. Securities Exchange Act of 1934, as
amended. Such forward-looking statements may include projections
regarding Lifeward's future performance and future regulatory
interactions and other statements that are not statements of
historical fact and, in some cases, may be identified by words like
"anticipate," "assume," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "future," "will," "should," "would," "seek" and similar
terms or phrases. The forward-looking statements contained in this
press release are based on management's current expectations, which
are subject to uncertainty, risks and changes in circumstances that
are difficult to predict and many of which are outside of
Lifeward’s control. Important factors that could cause the
Company’s actual results to differ materially from those indicated
in the forward-looking statements are more fully discussed in the
Company’s periodic filings with the Securities and Exchange
Commission (“SEC”), including the risk factors described under
the heading "Risk Factors" in the Company’s annual report on Form
10-K and 10-K/A for the year ended December 31,
2023 filed with the SEC and other documents
subsequently filed with or furnished to the SEC. Any
forward-looking statement made in this press release speaks only as
of the date hereof. Factors or events that could cause the
Company’s actual results to differ from the statements contained
herein may emerge from time to time, and it is not possible for the
Company to predict all of them. Except as required by law, Lifeward
undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future
developments or otherwise.
Lifeward Media Relations:Kathleen O’DonnellVP Marketing &
New Business DevelopmentLifewardE: media@golifeward.com
Lifeward Investor Contact:Mike LawlessChief Financial
OfficerLifewardE: ir@golifeward.com
Lifeward (NASDAQ:LFWD)
Historical Stock Chart
From Oct 2024 to Nov 2024
Lifeward (NASDAQ:LFWD)
Historical Stock Chart
From Nov 2023 to Nov 2024